Free Trial

Rigel Pharmaceuticals Q4 2022 Earnings Report

Rigel Pharmaceuticals logo
$20.13 +2.78 (+16.02%)
As of 01/17/2025 04:00 PM Eastern

Rigel Pharmaceuticals EPS Results

Actual EPS
$0.10
Consensus EPS
-$0.70
Beat/Miss
Beat by +$0.80
One Year Ago EPS
-$1.30

Rigel Pharmaceuticals Revenue Results

Actual Revenue
$51.28 million
Expected Revenue
$37.55 million
Beat/Miss
Beat by +$13.73 million
YoY Revenue Growth
N/A

Rigel Pharmaceuticals Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Rigel Pharmaceuticals Earnings Headlines

Equities Analysts Set Expectations for RIGL Q4 Earnings
Cantor Fitzgerald Brokers Raise Earnings Estimates for RIGL
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Rigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42M
See More Rigel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rigel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rigel Pharmaceuticals and other key companies, straight to your email.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ:RIGL), a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

View Rigel Pharmaceuticals Profile

More Earnings Resources from MarketBeat